Publicación Trimestral de Actualización Científica y Tecnológica para Médicos Veterinarios.
Acetato de Osaterona (Ypozane®) Bibliografía 1. Wanke M Gobello C. Reproducción en caninos y felinos domésticos. Edit Intermédica, Buenos Aires Argentina 2006 2. Prats Esteve. Patología protática canina, Edit Intermédica, Buenos Aires Argentina 2009 3. Pratique vét de l’Animal de Compagnie.SPÉCIAL HYPERPLASIE BÉNIGNE DE LA PROSTATE, Association Française des Vétérinaires pour Animaux de CompagnieSupplément au n°382007. 4. Shidaifat F. et al. 2004. Effect of androgen ablation on prostatic cell differentiation in dogs. Endocr. Res. 30 (3). 327-334. 5. J.A. Barsanti and D.R.Finco. Medical management of canine prostatic hyperplasia Current Veterinary Therapy XII. Kirk R.W. Philadelphia WB Saunders Co, 1995, 1033-1034 6. Allix V. et al. Pharmacokinetics of osaterone after repeated oral administration at 0.25 mg/ kg/day for 7 days. Proceedings of the 31th World Small Animal Veterinary Congress WSAVA 2006, 834-835. 7. Tsutsui T et al. Regression of Prostatic Hypertrophy by Osaterone acetate in dogs. J Vet Med Sci, 62, 10, 2000, 1115-9 8. Tsutsui T et al. Effect of osaterone acetate administration on prosatic regression rate, peripheral blood hormone levels and semen quality in dogs with begnin prostatic hypertrophy. J Vet Med Sci, 63, 4, 2001, 453-6 9. Albouy M. Treatment of benign prostatic hyperplasia with Osaterone acetate tablets. Proceedings of the 31th World Small Animal Veterinary Congress WSAVA 2006, 831-832. 10. Mimouni P. et al . Treatment of benign prostatic hyperplasia with Osaterone acetate tablets: a study in breeding dogs. Proceedings of the 5th Biannual EVSSAR congress, 2006, 303.
VIRBAC MÉXICO, S.A. DE C.V. Lote 30, Manzana I Parque Industrial Guadalajara El Salto Jalisco C.P 45690 www.virbac.com.mx Tel (01.33) 50.00.25.00 Fax (01.33) 50.00.25.15